China’s New Supply Chain Rules Pose Major Risks for Western Biopharma Firms

China’s Clinical Trial Dominance Grows, Raising Supply Chain Concerns

Western pharmaceutical executives are facing a stark reality: China has transformed from a minor player in global clinical trials to a dominant force. In 2010, China accounted for less than 8% of global trials, but by 2020, it surpassed the United States in annual registered trial volume. As of 2024, China conducts over 5,000 trials per year, with 88% of this growth driven by domestic Chinese firms—not multinational relocations of R&D.

New Regulations Grant Beijing Sweeping Powers

On April 7, 2024, China’s State Council issued Decree No. 834, the Regulations on Industrial and Supply Chain Security, effective immediately with no transition period. The decree consists of 18 articles that empower Beijing to investigate and sanction any foreign company whose commercial decisions are deemed to harm China’s industrial chain security.

China’s Strategic Focus on Biotech and Pharma

China’s 15th Five-Year Plan explicitly designates biotechnology and pharmaceuticals as the centerpiece of its next phase of industrial development. Decree No. 834 serves as the legal framework to protect and advance this ambition, signaling Beijing’s intent to assert greater control over global supply chains.

Western Biopharma Faces Unprecedented Risks

For Western biopharmaceutical companies, the implications are profound. China is no longer just a manufacturing hub—it has become a peer competitor in drug innovation. The new regulations create significant risks for foreign firms operating in or sourcing from China, as Beijing now holds the authority to intervene in commercial decisions under the guise of national security.

Experts warn that these measures could disrupt supply chains, delay drug development, and force Western companies to reconsider their reliance on China for critical components and research.